Clinical trials: Metastatic Prostate Adenocarcinoma
Prostate Cancer, Adenocarcinoma of the Prostate
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread…
- Trial name
- NCT00181558
- Testing
- Atrasentan, Zoledronic Acid (Zometa)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005857
- Testing
- trastuzumab, docetaxel
- Where
- 4 sites in United States
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
ATM Gene Mutation, BRCA1 Gene Mutation
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone
- Trial name
- NCT03442556
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Metastatic Castration-resistant Prostate Cancer
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- NCT06067841
- Testing
- BMS-986460
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004029
- Testing
- recombinant viral vaccine therapy, sargramostim
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07080242
- Testing
- BL-M14D1
- Where
- 31 sites in United States, Georgia and 1 more
- Volunteers
- 120 people
- Sponsor
- SystImmune Inc.
Metastatic Prostate Adenocarcinoma
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies
Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration
- Trial name
- OPALE (NCT03611686)
- Testing
- Local chemotherapy
- Where
- France
- Volunteers
- 219 people
- Sponsor
- University Hospital, Rouen
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT06312670
- Testing
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pedro Barata, MD, MSc
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Prostate cancer is a common and important health issue. Although effective treatment is often available for localized disease, metastatic prostate cancer remains incurable.
- Trial name
- NCT00574769
- Testing
- RAD001, Docetaxel, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
RATIONALE: Metformin hydrochloride may make some enzymes active. These enzymes may block other enzymes needed for cell growth and stop the growth of tumor cells.
- Trial name
- NCT01243385
- Testing
- Metformin
- Where
- 9 sites in Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Metastatic Prostatic Adenocarcinoma
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
- Trial name
- NCT04090775
- Testing
- Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Rampart Health, L.L.C.
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic
Prostate Cancer, Adenocarcinoma of the Prostate
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.
- Trial name
- NCT01394263
- Testing
- Histrelin hydrogel implant, Zoladex goserelin implant
- Volunteers
- 59 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company